The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Antitumor effects of dabrafenib, trametinib, and panitumumab as single agents and in combination in BRAF-mutant colorectal carcinoma (CRC) models.
LI Liu
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Hong Shi
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Maureen R Bleam
Employment or Leadership Position - GlaxoSmithKline
Vivian Zhang
Stock Ownership - GlaxoSmithKline
Jun Zou
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Junping Jing
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Kurtis E. Bachman
Stock Ownership - GlaxoSmithKline
Monica Motwani
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Keith W. Orford
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Axel Hoos
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline